IMVT News and Press, Immunovant Inc. From 05/29/24

Following a recently completed Type B meeting with the FDA, Immunovant is on track to initiate 4 to 5 potentially registrational studies for its lead asset IMVT-1402 in endocrinology, neurology, and other therapeutic areas over this fiscal year ending March 31, 2025 Topline data from the bato...

2024-05-29 14:30:03 ET Goldman Sachs analyst issues NEUTRAL recommendation for IMVT on May 29, 2024 12:26PM ET. The previous analyst recommendation was Neutral. IMVT was trading at $30.615 at issue of the analyst recommendation. The overall analyst consensus : BUY. C...

2024-05-29 10:00:15 ET More on Health Care Select Sector SPDR XLV: Healthcare Is Ripe For Buying, Despite Patent Cliff XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care Short interest in S&P 500 ...

2024-05-29 09:10:49 ET More on premarket gainers & stock D-Wave Quantum: Profitability Remains Elusive D-Wave Quantum Inc. (QBTS) Q1 2024 Earnings Call Transcript Semler Scientific: Great Product Can Still Thrive Post Medicare Advantage Semler Scientific ...

Fuse Medical Inc (FZMD) is expected to report for Q1 2024 PhoneX Holdings Inc (PXHI) is expected to report for Q1 2024 Avalon GloboCare Corp. (ALBT) is expected to report for Q1 2024 Ricoh Company Ltd ADR (RICOY) is expected to report for Q4 2024 Amplitech Group Inc. (AMPG) is exp...

2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...

2024-05-12 11:00:00 ET More on Acadia Pharma, BridgeBio Pharma, etc. ACADIA Pharmaceuticals Inc. (ACAD) Q1 2024 Earnings Call Transcript ACADIA Pharmaceuticals Inc. 2024 Q1 - Results - Earnings Call Presentation Rocket Pharmaceuticals: Cautiously Optimistic (Rating U...

2024-04-23 09:30:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended March 31, 2024, Baron Health Care Fund advanced 8.92% compared wi...

2024-04-04 02:12:07 ET Summary Immunovant's IMVT-1402 shows promise for at-home autoimmune treatment, with a differentiated subcutaneous delivery. Phase 1 data indicate significant IgG reductions without major side effects, advancing toward registrational trials. Financial hea...

2024-04-02 14:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...